Key facts
as of Oct 2026- Operator of a biotechnology company intended to develop novel vaccines using proprietary artificial cell membrane technology.
- ACM Biolabs is valued at approximately $92.7M as of Oct 2026 (last reported valuation).
- It has raised $26.0M; the latest was Later Stage VC ($2.9M) in May 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Coalition for Epidemic Preparedness Innovations, San Pacific Investments, Agency for Science, NTUitive — 9 tracked in total.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$92.7M
ACM Biolabs's last reported valuation, Sep 2022. Nothing priced has surfaced since.
Free account
More of ACM Biolabs with a free account
- ·Watch ACM Biolabs: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for ACM Biolabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About ACM Biolabs
Operator of a biotechnology company intended to develop novel vaccines using proprietary artificial cell membrane technology. The company develops prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, enabling medical researchers to develop effective vaccines.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2013
- Employees
- 19
- Website
- acmbiolabs.com/
- Ownership
- Privately Held (backing)